Dementia Risk Prediction Model: Development and Validation

NCT ID: NCT03943641

Last Updated: 2024-12-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

400000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-05-08

Study Completion Date

2024-12-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

At present, there is no treatment for dementia that changes the course of the disease. However, it is now understood that the proteins in dementias such as Alzheimer's disease are present years before someone develops symptoms of dementia. Studies may therefore need to give potential treatments to patients before they develop symptoms of dementia. To do this, researchers need a way of predicting who will go on to develop dementia in the future.

There are several ways of doing this, however, many of these methods are costly and difficult to implement at a population level - such as brain imaging, lumbar punctures or psychological tests. In this study, the investigators aim to develop a method of predicting who will go on to develop dementia (and dementia due to Alzheimer's disease) using only the sort of information that a general practitioner would have available to them.

To do this, the investigators will develop a dementia prediction model using data from the Secure Anonymised Information Linkage (SAIL) Databank, which contains anonymised primary care, hospital admissions and mortality data for the population of Wales, United Kingdom (UK). They will then go on to test how well it performs in an external dataset, such as the UK's Clinical Practice Research Datalink (CPRD).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To date, no dementia drugs have shown a disease-modifying effect in clinical trials. It is now understood that the pathology underlying Alzheimer's disease is present decades before symptoms become apparent. Starting an intervention only when a patient develops cognitive symptoms, and therefore when there is substantial disease burden, may reduce the chance of any disease-modifying effect. Instead, targeting interventions earlier, when the pathological burden is lower, may increase the likelihood of preventing or delaying dementia onset.

Consequently, there is a need for a method that identifies patients who are at an increased risk of developing dementia. This requires the development of a risk prediction model, which utilises multiple predictors in combination to produce individualised estimates of the risk of developing dementia risk over time.

An ideal risk prediction model for a population-based application would need to use predictors that are already available to, or readily obtainable by, general practitioners (GPs). Such a predictive tool could be used as a low cost, scalable method of recruiting an 'at risk' group of participants to future trials of risk modification strategies or preventative therapies. Once an effective disease-modifying intervention is identified, clinicians could use the same model to identify at-risk patients who may benefit most from undergoing the intervention.

An ideal dementia risk prediction tool would contain only information that is readily available to, or easily obtainable by, clinicians such as General Practitioners (GPs).

The investigators aim to develop two 10-year risk prediction models: one to predict all-cause dementia and one to predict Alzheimer's disease dementia, in UK adults aged 60-79 years, using only predictors that are routinely available to GPs. They will develop the model using data from the Secure Anonymised Information Linkage (SAIL) Databank, which is composed of anonymised, linked primary care, hospital admissions and mortality data for the population of Wales, UK.

The investigators will then go on to externally validate their dementia risk prediction models in an external dataset, such as the UK's Clinical Practice Research Datalink (CPRD). They will also validate an existing, published study using data from the The Health Improvement Network (THIN) (Walters et al. 2016) using this external dataset, allowing us to compare the performance of the models.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dementia Alzheimers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Population-based

Population-based cohort of participants registered with a SAIL-contributing practice.

This is not an intervention study

Intervention Type OTHER

This study is based on retrospective analysis of linked routinely-collected healthcare data

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

This is not an intervention study

This study is based on retrospective analysis of linked routinely-collected healthcare data

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Registered with a SAIL practice before 2008
* Aged between 60-79 during the study window (1st January 2008 to 31st December 2017)
* Aged 60-79 years by January 2008

Exclusion Criteria

* Deprivation quintile missing for the start of follow-up (deprivation scores will probably not be missing at random)
* All-cause dementia code in any dataset prior to 1st January 2008 (i.e. dementia diagnosis at baseline)
Minimum Eligible Age

60 Years

Maximum Eligible Age

79 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Keele University

OTHER

Sponsor Role collaborator

University of Edinburgh

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Usher Institute, University of Edinburgh

Edinburgh, Midlothian, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AC19049

Identifier Type: -

Identifier Source: org_study_id